Editas Research Development vs Income Before Tax Analysis
EDIT Stock | USD 5.21 0.16 2.98% |
Editas Medicine financial indicator trend analysis is much more than just examining Editas Medicine latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Editas Medicine is a good investment. Please check the relationship between Editas Medicine Research Development and its Income Before Tax accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.
Research Development vs Income Before Tax
Research Development vs Income Before Tax Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Editas Medicine Research Development account and Income Before Tax. At this time, the significance of the direction appears to have pay attention.
The correlation between Editas Medicine's Research Development and Income Before Tax is -0.92. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of Editas Medicine, assuming nothing else is changed. The correlation between historical values of Editas Medicine's Research Development and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Editas Medicine are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Research Development i.e., Editas Medicine's Research Development and Income Before Tax go up and down completely randomly.
Correlation Coefficient | -0.92 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Research Development
Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Editas Medicine income statement and is an important metric when analyzing Editas Medicine profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most indicators from Editas Medicine's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Editas Medicine current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.Enterprise Value is likely to gain to about 921.9 M in 2024, whereas Selling General Administrative is likely to drop slightly above 57.9 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 218.7M | 245.7M | 241.2M | 167.7M | Cost Of Revenue | 5.1M | 6.3M | 6.1M | 5.8M |
Editas Medicine fundamental ratios Correlations
Click cells to compare fundamentals
Editas Medicine Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Editas Medicine fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 508.9M | 572.6M | 677.5M | 514.3M | 499.2M | 395.9M | |
Short Long Term Debt Total | 29.1M | 26.1M | 26.4M | 43.9M | 36.5M | 33.9M | |
Other Current Liab | 24.8M | 24.0M | 20.2M | 31.3M | 34.6M | 36.3M | |
Total Current Liabilities | 60.0M | 58.2M | 46.9M | 60.1M | 63.2M | 40.9M | |
Total Stockholder Equity | 262.4M | 393.6M | 553.6M | 360.7M | 349.1M | 239.8M | |
Other Liab | 163.2M | 101.5M | 60.9M | 60.7M | 69.8M | 71.4M | |
Property Plant And Equipment Net | 39.6M | 39.1M | 43.3M | 59.2M | 45.7M | 35.0M | |
Net Debt | (209.1M) | (113.5M) | (177.1M) | (97.6M) | (87.1M) | (91.5M) | |
Retained Earnings | (549.2M) | (665.2M) | (857.7M) | (1.1B) | (1.2B) | (1.2B) | |
Accounts Payable | 5.8M | 6.4M | 5.1M | 9.5M | 8.3M | 5.3M | |
Cash | 238.2M | 139.7M | 203.5M | 141.5M | 123.7M | 146.9M | |
Non Current Assets Total | 45.0M | 153.5M | 170.2M | 157.6M | 158.3M | 82.0M | |
Non Currrent Assets Other | 107K | 4.7M | 6.8M | 5.3M | 4.7M | 3.3M | |
Other Assets | 1.7M | 4.7M | 6.8M | 5.3M | 6.0M | 6.3M | |
Cash And Short Term Investments | 457.1M | 511.8M | 619.9M | 437.4M | 323.1M | 338.9M | |
Common Stock Shares Outstanding | 50.0M | 58.6M | 67.6M | 68.7M | 76.0M | 49.3M | |
Liabilities And Stockholders Equity | 508.9M | 572.6M | 677.5M | 514.3M | 499.2M | 395.9M | |
Non Current Liabilities Total | 186.5M | 120.8M | 77.0M | 93.5M | 86.8M | 115.2M | |
Other Current Assets | 6.3M | 10.9M | 7.2M | 7.3M | 7.5M | 4.3M | |
Other Stockholder Equity | 811.5M | 1.1B | 1.4B | 1.4B | 1.6B | 1.7B | |
Total Liab | 246.4M | 179.0M | 123.8M | 153.6M | 150.1M | 156.1M | |
Property Plant And Equipment Gross | 39.6M | 39.1M | 58.8M | 80.7M | 72.0M | 41.4M | |
Total Current Assets | 463.8M | 419.1M | 507.3M | 356.8M | 340.8M | 314.0M | |
Accumulated Other Comprehensive Income | 107K | (46K) | (493K) | (3.6M) | 198K | 207.9K | |
Property Plant Equipment | 39.6M | 14.0M | 17.1M | 15.6M | 17.9M | 23.1M | |
Net Tangible Assets | 262.4M | 393.6M | 553.6M | 360.7M | 414.8M | 250.7M | |
Current Deferred Revenue | 23.5M | 20.9M | 11.3M | 8.2M | 9.5M | 14.2M | |
Net Receivables | 418K | 6.0M | 267K | 5.1M | 10.2M | 10.7M | |
Short Term Debt | 5.8M | 6.8M | 10.3M | 11.1M | 12.2M | 9.5M | |
Short Term Investments | 219.0M | 262.4M | 296.3M | 202.8M | 199.5M | 195.2M | |
Capital Surpluse | 811.5M | 1.1B | 1.4B | 1.4B | 1.7B | 854.8M | |
Retained Earnings Total Equity | (549.2M) | (665.2M) | (857.7M) | (1.1B) | (970.3M) | (921.8M) | |
Capital Lease Obligations | 29.1M | 26.1M | 26.4M | 43.9M | 36.5M | 36.2M |
Pair Trading with Editas Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Editas Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will appreciate offsetting losses from the drop in the long position's value.Moving together with Editas Stock
0.65 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
0.66 | VTRS | Viatris Financial Report 13th of May 2024 | PairCorr |
0.86 | EGRX | Eagle Pharmaceuticals | PairCorr |
0.8 | ELAN | Elanco Animal Health Financial Report 14th of May 2024 | PairCorr |
Moving against Editas Stock
0.82 | ACB | Aurora Cannabis Trending | PairCorr |
0.73 | CGC | Canopy Growth Corp Trending | PairCorr |
0.49 | FLGC | Flora Growth Corp Buyout Trend | PairCorr |
0.41 | HCM | HUTCHMED DRC | PairCorr |
The ability to find closely correlated positions to Editas Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Editas Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Editas Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Editas Medicine to buy it.
The correlation of Editas Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Editas Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Editas Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Editas Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Editas Stock analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.02) | Revenue Per Share 1.028 | Quarterly Revenue Growth 8.187 | Return On Assets (0.21) | Return On Equity (0.43) |
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.